Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM0N9WA)

Drug Name
Calcitonin Human Drug Info
Indication
Disease Entry ICD 11 Status REF
Paget's disease FB85 Approved [1]
Pain MG30-MG3Z Phase 3 [2]
Postmenopausal osteoporosis FB83.11 Phase 3 [2]
Therapeutic Class
Anticancer Agents
Cross-matching ID
PubChem CID
45055432
ChEBI ID
CHEBI:135973
TTD Drug ID
DM0N9WA

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcitonin receptor (CALCR) TTLWS2O CALCR_HUMAN Modulator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Calcitonin receptor (CALCR) DTT CALCR 5.326 4.489 4.213 5.07
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Paget's disease
ICD Disease Classification FB85
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Calcitonin receptor (CALCR) DTT CALCR 7.52E-03 0.17 2.26
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res. 2012 Aug;27(8):1821-9.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.